Labgenomics Co

Labgenomics Co FCF per Share

The Free Cash Flow per Share of Labgenomics Co (084650.KQ) as of Nov 14, 2026 is -3,547.47 KRW. In the previous year, Free Cash Flow per Share was -1,932.64 KRW — a change of 83.56% (lower).

FCF per Share

-3,547.47KRW

YoY

83.56%

Last updated:

Free Cash Flow per Share of Labgenomics Co is 2025 -3,547.47 KRW. Free Cash Flow per Share of Labgenomics Co was 2024 -1,932.64 KRW. It decreases by 83.56% lower compared to the previous year.

The Labgenomics Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-156.38 KRW
Jan 1, 2019
289.44 KRW
Jan 1, 2020
5,031.85 KRW
Jan 1, 2021
5,689.87 KRW
Jan 1, 2022
3,474.69 KRW
Jan 1, 2023
-305.67 KRW
Jan 1, 2024
-1,932.64 KRW
Jan 1, 2025
-3,547.47 KRW
The Labgenomics Co FCF per Share history
YEARFCF per ShareYoY
-3,547.47KRW+83.56%
-1,932.64KRW+532.27%
-305.67KRW-108.80%
3,474.69KRW-38.93%
5,689.87KRW+13.08%
5,031.85KRW+1,638.49%
289.44KRW-285.08%
-156.38KRW-75.16%
-629.53KRW+272.66%
-168.93KRW-31.83%
-247.81KRW-215.71%
214.17KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Free Cash Flow per Share of Labgenomics Co is -3,547.47 KRW in 2025.

Free Cash Flow per Share of Labgenomics Co changed from -1,932.64 KRW to -3,547.47 KRW, representing a 83.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Labgenomics Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Labgenomics Co